TY  - BOOK
AU  - Schijns, Virgil E. J. C.
AU  - O'Hagan,Derek T.
TI  - Immunopotentiators in modern vaccines
SN  - 0120884038 (alk. paper)
U1  - 615.372 22
PY  - 2006///
CY  - Amsterdam, Boston
PB  - Elsevier Academic Press
KW  - Immunological adjuvants
KW  - Immune response
KW  - Regulation
KW  - Vaccines
KW  - immunology
KW  - Adjuvants, Immunologic
KW  - Drug Delivery Systems
KW  - Immunotherapy
N1  - Contents

Contents
Part I. Perspective on Immunological mechanisms underlying adjuvant activity
 1) Unravelling "the immunologist's dirty little secret"
 Virgil Schijns

Part II. Host-derived immunopotentiators
 2) Dendritic cells as targets and tools in vaccines
 Filippo Belardelli, Imerio Capone and Paoloa Rizza
3) Host derived molecules and antibodies against them as adjuvants
 Tom Barr, Jennifer Carlring, Andrew W. Heath,

Part III. Natural and synthetic immunopotentiators
 4) Immune potentiator mechanisms
 Nick Valiante
 5) CpG Oligodeoxynucleotides as vaccine adjuvants
 Michael J. McCluskie and Risini D. Weeratna
 6) Toll-like receptor 4 agonists as vaccine adjuvants
David Persing, Patrick McGowan, Jay T. Evans, Christopher Cluff, Sally Mossman, David Johnson and Jory R. Baldridge
 7) Immunomodulatory adjuvants from Quillaja saponaria
 Charlotte Read Kensil
 
 Part IV. Particulate immunopotentiators and delivery systems
 8) Microparticles as vaccine delivery systems
 Derek T. O'Hagan
 9) MF59: A safe and potent adjuvant for human use
 Audino Podda , Giuseppe Del Guidice and Derek T. O'Hagan
 10) Development and evaluation of AS04, an novel an improved adjuvant system containing MPL and aluminium salt
 Nathalie Garcon, Marcelle van Mechelen and Martine Wettendorf
 11) Virosomes for vaccine delivery
 Ian C. Metcalfe and Reinhard Gluck
 12) The ISCOMATRIXTM adjuvant
 Debbie Drane and Martin Pearse
 13) Mineral adjuvants
 Erik B. Lindblad
 
 Part V. Mucosal/ non-parenteral adjuvants
14) Mucosal Adjuvants Based On Cholera Toxin and Escherichia Coli Heat-Labile Enterotoxin 
 Jan Holmgren
15) Transcutaneous Immunization using the Heat-labile Enterotoxin of E. coli as an Adjuvant
 Richard T. Kenney and Gregory M. Glenn
VI. Th-1/ CTL adjuvants
16) T cell adjuvants and novel strategies for their identification
Philippe Moingeon

Part VII. Adjuvants in non-infectious disease vaccines
17) Vaccination to treat non-infectious diseases: surveying the opportunities
Stephen W. Martin and Martin F Bachmann

Part VIII. Clinical Practice
18) Clinical evaluation of adjuvants
Robert Edelman and Jakub K Simon
19) Non-clinical safety assessment of vaccines
Elizabeth M Sutkowski and Marion F Gruber; Includes bibliographical references and index
UR  - http://www.loc.gov/catdir/toc/ecip0514/2005016429.html
UR  - http://www.loc.gov/catdir/enhancements/fy0622/2005016429-d.html
ER  -